A STUDY OF ONARTUZUMAB (METMAB) IN COMBINATION WITH TARCEVA (ERLOTINIB) IN PARTICIPANTS WITH MET DIAGNOSTIC-POSITIVE NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED CHEMOTHERAPY FOR ADVANCED OR METASTATIC DISEASE (METLUNG):